What the Clinical Evidence Actually Shows
TRT safety has been debated for decades, but the science has matured dramatically in recent years. Large-scale randomized trials have addressed the biggest historical concerns — and the results may surprise you.
Cardiovascular Safety: The TRAVERSE Trial
The landmark TRAVERSE trial (2023) was the largest randomized controlled study of TRT safety ever conducted — 5,246 men followed over an average of 33 months. The results: no increase in major adverse cardiac events (heart attack, stroke, death) with TRT vs. placebo. The TRT group also showed a 22% lower rate of new-onset diabetes.
A 2015 Veterans Affairs study of 83,010 men found that men who achieved normal testosterone levels through TRT had 56% lower all-cause mortality, 24% fewer heart attacks, and 36% fewer strokes compared to untreated men with low T.
Prostate Safety
The belief that testosterone "feeds" prostate cancer dates back to a 1941 case report and has been thoroughly re-examined. In December 2025, an FDA expert panel recommended removing the prostate cancer warning from TRT labels, calling it unsupported by modern evidence. The TRAVERSE trial found no increased prostate cancer risk. Multiple meta-analyses confirm no causal link between TRT and prostate cancer in properly screened men.
TRT remains contraindicated in men with active, untreated prostate cancer. Regular PSA monitoring is standard protocol.
The Risks That Are Real
Polycythemia (5-10% of patients), estrogen elevation, fertility suppression, and acne are the documented side effects. All are manageable with proper monitoring. The key word is "monitoring" — TRT is safe when supervised by a competent provider who tracks your labs regularly and adjusts accordingly.
The FDA panel concluded that testosterone has been regulated as if it were a dangerous performance-enhancing drug — a classification not supported by current clinical evidence.
When TRT Is NOT Safe
Active untreated prostate cancer, breast cancer, severe untreated sleep apnea, uncontrolled heart failure, hematocrit above 54%, and planning for immediate conception. These are contraindications, not side effects — they should be screened for before treatment begins.